Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 39

1.

EGFR mutation subtypes and response to immune checkpoint blockade treatment in non-small cell lung cancer.

Hastings K, Yu H, Wei W, Sanchez-Vega F, DeVeaux M, Choi J, Rizvi H, Lisberg A, Truini A, Lydon CA, Liu Z, Henick BS, Wurtz A, Cai G, Plodkowski AJ, Long NM, Halpenny DF, Killam J, Oliva I, Schultz N, Riely GJ, Arcila ME, Ladanyi M, Zelterman D, Herbst RS, Goldberg SB, Awad MM, Garon EB, Gettinger S, Hellmann MD, Politi K.

Ann Oncol. 2019 May 14. pii: mdz141. doi: 10.1093/annonc/mdz141. [Epub ahead of print]

2.

Tumor Volume Analysis as a Predictive Marker for Prolonged Survival in Anaplastic Lymphoma Kinase-rearranged Advanced Non-Small Cell Lung Cancer Patients Treated With Crizotinib.

Hida T, Dahlberg SE, Lydon CA, Hatabu H, Johnson BE, Awad MM, Nishino M.

J Thorac Imaging. 2019 Apr 12. doi: 10.1097/RTI.0000000000000413. [Epub ahead of print]

PMID:
30985604
3.

Interstitial lung abnormality in stage IV non-small cell lung cancer: A validation study for the association with poor clinical outcome.

Araki T, Dahlberg SE, Hida T, Lydon CA, Rabin MS, Hatabu H, Johnson BE, Nishino M.

Eur J Radiol Open. 2019 Mar 29;6:128-131. doi: 10.1016/j.ejro.2019.03.003. eCollection 2019.

4.

M1b Disease in the 8th Edition of TNM Staging of Lung Cancer: Pattern of Single Extrathoracic Metastasis and Clinical Outcome.

Park H, Dahlberg SE, Lydon CA, Araki T, Hatabu H, Rabin MS, Johnson BE, Nishino M.

Oncologist. 2019 Aug;24(8):e749-e754. doi: 10.1634/theoncologist.2018-0596. Epub 2019 Jan 29.

PMID:
30696724
5.

Virtual monitoring of suicide risk in the general hospital and emergency department.

Kroll DS, Stanghellini E, DesRoches SL, Lydon C, Webster A, O'Reilly M, Hurwitz S, Aylward PM, Cartright JA, McGrath EJ, Delaporta L, Meyer AT, Kristan MS, Falaro LJ, Murphy C, Karno J, Pallin DJ, Schaffer A, Shah SB, Lakatos BE, Mitchell MT, Murphy CA, Gorman JM, Gitlin DF, Mulloy DF.

Gen Hosp Psychiatry. 2019 Jan 14. pii: S0163-8343(18)30222-6. doi: 10.1016/j.genhosppsych.2019.01.002. [Epub ahead of print]

PMID:
30665667
6.

Impact of BRAF Mutation Class on Disease Characteristics and Clinical Outcomes in BRAF-mutant Lung Cancer.

Dagogo-Jack I, Martinez P, Yeap BY, Ambrogio C, Ferris LA, Lydon C, Nguyen T, Jessop NA, Iafrate AJ, Johnson BE, Lennerz JK, Shaw AT, Awad MM.

Clin Cancer Res. 2019 Jan 1;25(1):158-165. doi: 10.1158/1078-0432.CCR-18-2062. Epub 2018 Sep 17.

PMID:
30224342
7.

Tumor innate immunity primed by specific interferon-stimulated endogenous retroviruses.

Cañadas I, Thummalapalli R, Kim JW, Kitajima S, Jenkins RW, Christensen CL, Campisi M, Kuang Y, Zhang Y, Gjini E, Zhang G, Tian T, Sen DR, Miao D, Imamura Y, Thai T, Piel B, Terai H, Aref AR, Hagan T, Koyama S, Watanabe M, Baba H, Adeni AE, Lydon CA, Tamayo P, Wei Z, Herlyn M, Barbie TU, Uppaluri R, Sholl LM, Sicinska E, Sands J, Rodig S, Wong KK, Paweletz CP, Watanabe H, Barbie DA.

Nat Med. 2018 Aug;24(8):1143-1150. doi: 10.1038/s41591-018-0116-5. Epub 2018 Jul 23.

8.

Safety and Efficacy of PD-1 Inhibitors Among HIV-Positive Patients With Non-Small Cell Lung Cancer.

Ostios-Garcia L, Faig J, Leonardi GC, Adeni AE, Subegdjo SJ, Lydon CA, Rangachari D, Huberman MS, Sehgal K, Shea M, VanderLaan PA, Cheng MP, Marty FM, Hammond SP, Costa DB, Awad MM.

J Thorac Oncol. 2018 Jul;13(7):1037-1042. doi: 10.1016/j.jtho.2018.03.031. Epub 2018 Apr 6.

9.

Epitope mapping of spontaneous autoantibodies to anaplastic lymphoma kinase (ALK) in non-small cell lung cancer.

Awad MM, Mastini C, Blasco RB, Mologni L, Voena C, Mussolin L, Mach SL, Adeni AE, Lydon CA, Sholl LM, Jänne PA, Chiarle R.

Oncotarget. 2017 Sep 23;8(54):92265-92274. doi: 10.18632/oncotarget.21182. eCollection 2017 Nov 3.

10.

Reluctance to fail nursing students in practice-implications for nurse managers.

Timmins F, Cassidy S, Nugent O, Lydon C, Part S, Keane L, Dennehy C, Fenn H, Prizeman G, Murphy F, Coffey M.

J Nurs Manag. 2017 Oct;25(7):489-490. doi: 10.1111/jonm.12508. No abstract available.

PMID:
29024202
11.

Tumor Response Dynamics of Advanced Non-small Cell Lung Cancer Patients Treated with PD-1 Inhibitors: Imaging Markers for Treatment Outcome.

Nishino M, Dahlberg SE, Adeni AE, Lydon CA, Hatabu H, Jänne PA, Hodi FS, Awad MM.

Clin Cancer Res. 2017 Oct 1;23(19):5737-5744. doi: 10.1158/1078-0432.CCR-17-1434. Epub 2017 Jul 5.

12.

Response Heterogeneity of EGFR and HER2 Exon 20 Insertions to Covalent EGFR and HER2 Inhibitors.

Kosaka T, Tanizaki J, Paranal RM, Endoh H, Lydon C, Capelletti M, Repellin CE, Choi J, Ogino A, Calles A, Ercan D, Redig AJ, Bahcall M, Oxnard GR, Eck MJ, Jänne PA.

Cancer Res. 2017 May 15;77(10):2712-2721. doi: 10.1158/0008-5472.CAN-16-3404. Epub 2017 Mar 31.

13.

Cost and Survival Analysis Before and After Implementation of Dana-Farber Clinical Pathways for Patients With Stage IV Non-Small-Cell Lung Cancer.

Jackman DM, Zhang Y, Dalby C, Nguyen T, Nagle J, Lydon CA, Rabin MS, McNiff KK, Fraile B, Jacobson JO.

J Oncol Pract. 2017 Apr;13(4):e346-e352. doi: 10.1200/JOP.2017.021741. Epub 2017 Mar 4.

PMID:
28260402
14.

Assigning clinical meaning to somatic and germ-line whole-exome sequencing data in a prospective cancer precision medicine study.

Ghazani AA, Oliver NM, St Pierre JP, Garofalo A, Rainville IR, Hiller E, Treacy DJ, Rojas-Rudilla V, Wood S, Bair E, Parello M, Huang F, Giannakis M, Wilson FH, Stover EH, Corsello SM, Nguyen T, Rana HQ, Church AJ, Lowenstein C, Cibulskis C, Amin-Mansour A, Heng J, Brais L, Santos A, Bauer P, Waldron A, Lo P, Gorman M, Lydon CA, Welch M, McNamara P, Gabriel S, Sholl LM, Lindeman NI, Garber JE, Joffe S, Van Allen EM, Gray SW, Ja Nne PA, Garraway LA, Wagle N.

Genet Med. 2017 Jul;19(7):787-795. doi: 10.1038/gim.2016.191. Epub 2017 Jan 26.

PMID:
28125075
15.

Acquired METD1228V Mutation and Resistance to MET Inhibition in Lung Cancer.

Bahcall M, Sim T, Paweletz CP, Patel JD, Alden RS, Kuang Y, Sacher AG, Kim ND, Lydon CA, Awad MM, Jaklitsch MT, Sholl LM, Jänne PA, Oxnard GR.

Cancer Discov. 2016 Dec;6(12):1334-1341. Epub 2016 Sep 30.

16.

Teratogenicity of Ochratoxin A and the Degradation Product, Ochratoxin α, in the Zebrafish (Danio rerio) Embryo Model of Vertebrate Development.

Haq M, Gonzalez N, Mintz K, Jaja-Chimedza A, De Jesus CL, Lydon C, Welch A, Berry JP.

Toxins (Basel). 2016 Feb 5;8(2):40. doi: 10.3390/toxins8020040.

17.

Five-Year Survival in EGFR-Mutant Metastatic Lung Adenocarcinoma Treated with EGFR-TKIs.

Lin JJ, Cardarella S, Lydon CA, Dahlberg SE, Jackman DM, Jänne PA, Johnson BE.

J Thorac Oncol. 2016 Apr;11(4):556-65. doi: 10.1016/j.jtho.2015.12.103. Epub 2015 Dec 25.

18.

Rearrangement of {α-P2W15} to {PW6} moieties during the assembly of transition-metal-linked polyoxometalate clusters.

Martin-Sabi M, Winter RS, Lydon C, Cameron JM, Long DL, Cronin L.

Chem Commun (Camb). 2016 Jan 18;52(5):919-21. doi: 10.1039/c5cc08486e.

PMID:
26581307
19.

Expression of PD-1 and Its Ligands, PD-L1 and PD-L2, in Smokers and Never Smokers with KRAS-Mutant Lung Cancer.

Calles A, Liao X, Sholl LM, Rodig SJ, Freeman GJ, Butaney M, Lydon C, Dahlberg SE, Hodi FS, Oxnard GR, Jackman DM, Jänne PA.

J Thorac Oncol. 2015 Dec;10(12):1726-35. doi: 10.1097/JTO.0000000000000687.

20.

Long-term Benefit of PD-L1 Blockade in Lung Cancer Associated with JAK3 Activation.

Van Allen EM, Golay HG, Liu Y, Koyama S, Wong K, Taylor-Weiner A, Giannakis M, Harden M, Rojas-Rudilla V, Chevalier A, Thai T, Lydon C, Mach S, Avila AG, Wong JA, Rabin AR, Helmkamp J, Sholl L, Carter SL, Oxnard G, Janne P, Getz G, Lindeman N, Hammerman PS, Garraway LA, Hodi FS, Rodig SJ, Dranoff G, Wong KK, Barbie DA.

Cancer Immunol Res. 2015 Aug;3(8):855-63. doi: 10.1158/2326-6066.CIR-15-0024. Epub 2015 May 26.

21.

Immunohistochemical Loss of LKB1 Is a Biomarker for More Aggressive Biology in KRAS-Mutant Lung Adenocarcinoma.

Calles A, Sholl LM, Rodig SJ, Pelton AK, Hornick JL, Butaney M, Lydon C, Dahlberg SE, Oxnard GR, Jackman DM, Jänne PA.

Clin Cancer Res. 2015 Jun 15;21(12):2851-60. doi: 10.1158/1078-0432.CCR-14-3112. Epub 2015 Mar 3.

22.

Interstitial lung abnormalities in treatment-naïve advanced non-small-cell lung cancer patients are associated with shorter survival.

Nishino M, Cardarella S, Dahlberg SE, Araki T, Lydon C, Jackman DM, Rabin MS, Hatabu H, Johnson BE.

Eur J Radiol. 2015 May;84(5):998-1004. doi: 10.1016/j.ejrad.2015.01.021. Epub 2015 Feb 7.

23.

Prognostic impact of KRAS mutation subtypes in 677 patients with metastatic lung adenocarcinomas.

Yu HA, Sima CS, Shen R, Kass S, Gainor J, Shaw A, Hames M, Iams W, Aston J, Lovly CM, Horn L, Lydon C, Oxnard GR, Kris MG, Ladanyi M, Riely GJ.

J Thorac Oncol. 2015 Mar;10(3):431-7. doi: 10.1097/JTO.0000000000000432.

24.

Exploring the programmable assembly of a polyoxometalate-organic hybrid via metal ion coordination.

Yin P, Li T, Forgan RS, Lydon C, Zuo X, Zheng ZN, Lee B, Long D, Cronin L, Liu T.

J Am Chem Soc. 2013 Sep 11;135(36):13425-32. doi: 10.1021/ja404777g. Epub 2013 Aug 29.

PMID:
23931331
25.

Clinical, pathologic, and biologic features associated with BRAF mutations in non-small cell lung cancer.

Cardarella S, Ogino A, Nishino M, Butaney M, Shen J, Lydon C, Yeap BY, Sholl LM, Johnson BE, Jänne PA.

Clin Cancer Res. 2013 Aug 15;19(16):4532-40. doi: 10.1158/1078-0432.CCR-13-0657. Epub 2013 Jul 5.

26.

Directed assembly of nanoscale Co(II)-substituted {Co9[P2W15]3} and {Co14[P2W15]4} polyoxometalates.

Lydon C, Sabi MM, Symes MD, Long DL, Murrie M, Yoshii S, Nojiri H, Cronin L.

Chem Commun (Camb). 2012 Oct 11;48(79):9819-21. doi: 10.1039/c2cc34865a. Epub 2012 Aug 30.

PMID:
22935655
27.

Students experiences of theatre allocations.

Lydon C, Burke E.

J Perioper Pract. 2012 Feb;22(2):45-9. Review. No abstract available.

PMID:
22724303
28.

Controllable self-assembly of organic-inorganic amphiphiles containing Dawson polyoxometalate clusters.

Yin P, Pradeep CP, Zhang B, Li FY, Lydon C, Rosnes MH, Li D, Bitterlich E, Xu L, Cronin L, Liu T.

Chemistry. 2012 Jun 25;18(26):8157-62. doi: 10.1002/chem.201200362. Epub 2012 May 22.

PMID:
22618885
29.

Nanoscale growth of molecular oxides: assembly of a {V6} double cubane between two lacunary {P2W15} polyoxometalates.

Lydon C, Busche C, Miras HN, Delf A, Long DL, Yellowlees L, Cronin L.

Angew Chem Int Ed Engl. 2012 Feb 27;51(9):2115-8. doi: 10.1002/anie.201105829. Epub 2012 Feb 1. No abstract available.

PMID:
22298462
30.

Amphiphilic properties of dumbbell-shaped inorganic-organic-inorganic molecular hybrid materials in solution and at an interface.

Misdrahi MF, Wang M, Pradeep CP, Li FY, Lydon C, Xu L, Cronin L, Liu T.

Langmuir. 2011 Aug 2;27(15):9193-202. doi: 10.1021/la2013914. Epub 2011 Jun 30.

PMID:
21661766
31.

Design and synthesis of "dumb-bell" and "triangular" inorganic-organic hybrid nanopolyoxometalate clusters and their characterisation through ESI-MS analyses.

Pradeep CP, Li FY, Lydon C, Miras HN, Long DL, Xu L, Cronin L.

Chemistry. 2011 Jun 27;17(27):7472-9. doi: 10.1002/chem.201100257. Epub 2011 May 18.

PMID:
21594915
32.

Psychosocial programming in ireland based on the model of human occupation: a program evaluation study.

Turner N, Lydon C.

Occup Ther Health Care. 2008;22(2-3):105-14. doi: 10.1080/07380570801989564.

PMID:
23941377
33.

The mechanical properties of human alar and transverse ligaments at slow and fast extension rates.

Panjabi MM, Crisco JJ 3rd, Lydon C, Dvorak J.

Clin Biomech (Bristol, Avon). 1998 Mar;13(2):112-120.

PMID:
11415778
34.

Too slap happy.

Lydon C.

Nurs Times. 1996 Nov 6-12;92(45):48-9. No abstract available.

PMID:
9000977
35.

Effect of elongation rate on the failure properties of the rabbit anterior cruciate ligament.

Lydon C, Crisco J, Panjabi M, Galloway M.

Clin Biomech (Bristol, Avon). 1995 Dec;10(8):428-433.

PMID:
11415590
36.

On the understanding of clinical instability.

Panjabi MM, Lydon C, Vasavada A, Grob D, Crisco JJ 3rd, Dvorak J.

Spine (Phila Pa 1976). 1994 Dec 1;19(23):2642-50.

PMID:
7899958
37.

[The unstable spine--an "in vitro" and "in vivo study" on better understanding of clinical instability].

Grob D, Panjabi M, Dvorak J, Humke T, Lydon C, Vasavada A, Crisco J 3rd.

Orthopade. 1994 Aug;23(4):291-8. German.

PMID:
7970687
38.

Anular incision technique on the strength and multidirectional flexibility of the healing intervertebral disc.

Ahlgren BD, Vasavada A, Brower RS, Lydon C, Herkowitz HN, Panjabi MM.

Spine (Phila Pa 1976). 1994 Apr 15;19(8):948-54.

PMID:
8009354
39.

Employment rehabilitation: the role of the ERC.

Lydon C.

Community Health (Bristol). 1978 Feb;9(3):126-33. No abstract available.

PMID:
630833

Supplemental Content

Support Center